2013 Current Fiscal Year Report: Veterinary Medicine Advisory Committee

Report Run Date: 06/30/2025 09:43:42 PM

1. Department or Agency 2. Fiscal Year

Department of Health and Human

Services

3b. GSA Committee
3. Committee or Subcommittee

No.

2013

Veterinary Medicine Advisory

Committee

1042

4. Is this New During 5. Current 6. Expected 7. Expected Fiscal Year? Charter Renewal Date Term Date

No 04/24/2012 04/24/2014

8a. Was Terminated During 8b. Specific Termination Authority 8c. Actual Term Date

Yes 09/24/2013

9. Agency 10b.

Recommendation for Next Req to Terminate?

FiscalYear Pending?

Legislation Pending?

Continue No Not Applicable

11. Establishment Authority Authorized by Law

12. Specific 13. 14.

Establishment Effective Committee Presidential?

Authority Date Type

21 U.S.C. 394 11/28/1990 Continuing No

15. Description of Committee Scientific Technical Program

Advisory Board

16a. Total

No Reports for this FiscalYear

Reports

17a. 0 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 0

Meetings and Dates

No Meetings

	Current FY	Next FY
18a(1). Personnel Pmts	\$0.00	\$0.00
to Non-Federal Members		
18a(2). Personnel Pmts	\$0.00	\$0.00
to Federal Members		
18a(3). Personnel Pmts	\$51,535.00	\$0.00
to Federal Staff		
18a(4). Personnel Pmts		
to Non-Member	\$0.00	\$0.00
Consultants		
18b(1). Travel and Per	Ф0.00	40.00
Diem to Non-Federal	\$0.00	\$0.00
Members		
18b(2). Travel and Per	# 0.00	#0.00
Diem to Federal	\$0.00	\$0.00
Members		
18b(3). Travel and Per	\$0.00	\$0.00
Diem to Federal Staff		
18b(4). Travel and Per	# 0.00	#0.00
Diem to Non-member	\$0.00	\$0.00
Consultants		
18c. Administrative		
Costs (FRNs, contractor	ድር ርር	\$0.00
support,	\$0.00	φυ.υυ
In-person/hybrid/virtual meetings)		
18d. Other (all other		
funds not captured by	\$12,884.00\$	50 649 00
any other cost category)	Ψ12,004.00Ψ	30,043.00
18e. Total Costs	\$64,419.00\$	50.649.00
19. Federal Staff Support	. ,	22,210.00
Years (FTE)	0.30	0.30

20a. How does the Committee accomplish its purpose?

The Veterinary Medicine Advisory Committee advises the Commissioner in discharging their

responsibilities as they relate to assuring safe and effective drugs, feeds and feed additives, and devices for animal use, and, as required, any other product for which the Food and Drug Administration has regulatory responsibility.

20b. How does the Committee balance its membership?

The Committee consists of a core of 13 voting members including the Chair, who are knowledgeable of the issues related to the Committee's function. Members and the Chair are selected by the Commissioner, or designee, from among authorities knowledgeable in the fields of companion animal medicine, food animal medicine, avian medicine, microbiology, biometrics, toxicology, pathology, pharmacology, animal science, chemistry, public health/epidemiology and minor species/minor use veterinary medicine. One member is technically qualified and identified with consumer interests. The committee may also include one non-voting member who is identified with industry interests.

20c. How frequent and relevant are the Committee Meetings?

The VMAC did not meet during FY2013. The VMAC was terminated September 24, 2013.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

Members of the committee are drawn from academia, research, and/or clinical practice. Their advice and input lends credibility to regulatory decisions and helps those decisions stand up to intense public scrutiny. The alternate means of obtaining this advice would involve the recruitment of large numbers of scientists on a full-time basis at maximum rates of compensation.

20e. Why is it necessary to close and/or partially closed committee meetings?

There were no closed meetings to report in FY-13. The committee was terminated September 24, 2013.

21. Remarks

No reports required for FY-13. Although this committee did not meet in FY-13, considerable time was devoted to finding our whether or not the committee should be terminated. It was found on September 24, 2013 that the agency no longer needed the committee so it was terminated.

Designated Federal Officer

Aleta M. Sindelar Executive Secretary

Committee Members	Start	End	Occupation	Member Designation
Apley, Michael	03/09/2009	10/31/2012	Associate Professor, Kansas State University	Special Government Employee (SGE) Member
Poppenga, Robert	03/09/2009	10/31/2012	Professor of Clinical Toxicology, University of California @ Davis	Special Government Employee (SGE) Member
Senior, David	03/09/2009	10/31/2012	Associate Dean, Advancement & Strategic Init., Louisiana State University	Special Government Employee (SGE) Member
Stromberg, Paul	03/09/2009	10/31/2012	Professor of Veterinary Pathology, Ohio State University	Special Government Employee (SGE) Member

Number of Committee Members Listed: 4

Narrative Description

FDA's strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence and accountability. The Veterinary Medicine Advisory Committee supports FDA's strategic priorities by advising the Commissioner or designee in discharging responsibilities as they relate to helping to ensure public and animal health by approving safe and effective animal drugs and, as required, any other product for which the Food and Drug Administration has regulatory responsibility.

What are the most significant program outcomes associated with this committee?

C	hecked if
Α	pplies
Improvements to health or safety	✓
Trust in government	✓
Major policy changes	✓
Advance in scientific research	Y
Effective grant making	
Improved service delivery	
Increased customer satisfaction	Y
Implementation of laws or regulatory	
requirements	i.X.i
Other	
Outcome Comments	
NA	
What are the cost savings associated with this	
	necked if Applies
None	
Unable to Determine	Y
Under \$100,000	

\$100,000 - \$500,000

\$500,001 - \$1,000,000	
\$1,000,001 - \$5,000,000	
\$5,000,001 - \$10,000,000	
Over \$10,000,000	
Cost Savings Other	

Cost Savings Comments

The utilization of the Veterinary Medicine Advisory Committee enables the Agency to obtain required and frequently scarce professional services from medical and scientific experts not otherwise available to the Agency; and to obtain the services of these experts only on an as needed basis rather than on a full time basis. The service of the committee resulted in advice for the improvement of the public health, for which it is difficult to assign a financial value.

What is the approximate <u>Number</u> of recommendations produced by this committee for the life of the committee?

6

Number of Recommendations Comments

The committee met six times since FY2003 to discuss and make a collective recommendation on six separate issues. Each meeting transcript can be found at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/VeterinaryMedicineAdvisoryCommittees/CommitteesMeetingMaterials/VeterinaryMedicineAdvisoryCommitteesMeetingMaterials/VeterinaryMedic

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Fully</u> implemented by the agency?

80%

% of Recommendations Fully Implemented Comments

The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Partially</u> implemented by the agency?

10%

% of Recommendations Partially Implemented Comments

The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice. Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered? Yes 🗸 No Not Applicable **Agency Feedback Comments** It usually does. Product approval issues are first released to the sponsor. When appropriate, information is made available to the public. Actions related to guidance documents or other general matters issues are available publicly when implemented. What other actions has the agency taken as a result of the committee's advice or recommendation? Checked if Applies Reorganized Priorities Reallocated resources Issued new regulation Proposed legislation Approved grants or other payments Other **Action Comments** FDA approves or chooses not to approve an investigational new medical or food product. Is the Committee engaged in the review of applications for grants? No **Grant Review Comments** NA How is access provided to the information for the Committee's documentation? Checked if Applies Contact DFO Online Agency Web Site

Online Committee Web Site

Online GSA FACA Web Site	✓
Publications	✓
Other	

Access Comments

N/A